Pfizer’s Blockbuster Migraine Portfolio Plan On Track With Zavzpret Approval

Second Product From $11.6bn Biohaven Acquisition

 
• By Mandy Jackson

Pfizer plans to build on the momentum gained for its oral drug Nurtec ODT, now the leading CGRP inhibitor, with the intranasal Zavzpret, which will be priced in line with the rest of the class. 

Woman having headache, migraine. Cartoon vector illustration.
Zavzpret provided rapid pain and symptom relief in its Phase III trial • Source: Shutterstock

More from New Products

More from Scrip